Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vicarious Surgical Inc. filings document the company's robotic surgery business, capital structure, governance actions, and public-market status. Recent 8-K reports cover operating results, financial condition, executive employment agreement amendments, and NYSE delisting proceedings for the company's Class A common stock, which is quoted on the OTC market under RBOT.
Proxy and shareholder-vote filings describe amendments to the certificate of incorporation related to a reverse stock split authorization and the voting mechanics of the company's Class A and Class B common stock. Form 25 and related reports document removal of the Class A common stock from NYSE listing and registration under Section 12(b).
Vicarious Surgical Inc. reported a Q1 2026 net loss of $7,329k with no revenue as it continues developing its surgical robotic system. Operating expenses fell 52% year over year to $7,502k, driven by a roughly 60%+ reduction in headcount and lower R&D, sales and administrative spending.
Cash, cash equivalents and short-term investments totaled $3,682k as of March 31, 2026, and management states this is only expected to fund operations through the second quarter of 2026. The filing explicitly notes substantial doubt about the company’s ability to continue as a going concern unless it raises additional capital.
On March 3, 2026, the NYSE suspended trading and began delisting proceedings for the Class A common stock after the company fell below the exchange’s market capitalization standard; shares now trade on the OTCQB under “RBOT,” and the company is seeking a Nasdaq listing and has stockholder approval for a potential reverse stock split.
Vicarious Surgical Inc. held a special stockholder meeting where investors approved an amendment to its Certificate of Incorporation to enable a reverse stock split of its Class A and Class B common stock at a ratio between 1-for-2 and 1-for-30, with the exact ratio to be set by the Board.
Stockholders representing 1,885,434 shares, or about 60.68% of the total voting power, were present, satisfying quorum requirements. The reverse stock split proposal passed with 11,810,046 votes for, 49,675 against, and 3,430 abstentions, indicating strong support for giving the Board flexibility to adjust the share count and price structure.
Innovation Endeavors III and Dror Berman filed an amended Schedule 13D to update their ownership in Vicarious Surgical Inc. Class A common stock. They report beneficial ownership of 221,038 shares, or 3.4% of the class, based on 6,470,228 shares outstanding as of March 16, 2026.
The filing shows that Innovation Endeavors made a series of open market sales from March 20 to April 6, 2026 at weighted average prices between $0.70 and $1.06 per share. As a result, the reporting persons state they ceased to be beneficial owners of more than five percent of the Class A common stock on April 6, 2026.
Vicarious Surgical Inc. is asking stockholders to approve a reverse stock split of its Class A and Class B common stock, at a ratio between 1‑for‑2 and 1‑for‑30, with the exact ratio and timing to be set later by the board of directors or abandoned entirely.
The main goal is to raise the per‑share price of Class A stock to help qualify for an uplisting to the Nasdaq Capital Market after the New York Stock Exchange suspended trading and began delisting proceedings for failing to meet its $15 million market capitalization standard. The company’s Class A shares now trade on the OTC Markets under the symbol “RBOT.”
The proxy explains that a reverse split would reduce outstanding shares, proportionately adjust options, warrants and other equity awards, and pay cash instead of issuing fractional shares. It also notes potential risks, including no guarantee of a higher or sustained share price and possible lower trading liquidity, while authorized share counts would remain unchanged, increasing the number of shares available for future issuance.
Vicarious Surgical Inc. notified the New York Stock Exchange LLC to remove its Class A Common Stock from listing and/or registration. The Exchange states it has complied with rules to strike the class and the issuer "has complied with its rules of the Exchange" governing the voluntary withdrawal.
Vicarious Surgical Inc. is asking shareholders to approve an amendment to its Certificate of Incorporation to authorize a reverse stock split of Class A and Class B common stock at a ratio of not less than 1-for-2 and not greater than 1-for-30, with the Board to select the exact ratio and timing if approved.
The Board approved the proposal on March 13, 2026 and recommends approval. The company says the primary intent is to raise the per-share trading price of Class A common stock to help meet Nasdaq initial listing bid-price requirements, after the NYSE suspended trading and commenced delisting proceedings; Class A shares currently trade on the OTCID tier under symbol RBOT. The proxy discloses February 28, 2026 outstanding totals of 6,468,185 shares of Class A common stock and 653,990 shares of Class B common stock for beneficial ownership calculations. The Board may abandon the amendment at any time prior to filing the Certificate of Amendment. Approval requires the affirmative vote of a majority of votes cast.
Vicarious Surgical Inc. reported continued operating losses and confirmed that its common stock has been delisted from the New York Stock Exchange and is now quoted on the OTCID market.
For 2025, the company posted a net loss of $50.2 million, lower than the $63.2 million net loss in 2024. Total operating expenses fell to $50.0 million from $66.6 million, reflecting reduced research and development and general and administrative spending.
Liquidity weakened materially: cash and cash equivalents were $2.6 million and short-term investments $7.2 million at December 31, 2025, down from $9.7 million and $39.4 million a year earlier. Total assets declined to $19.6 million and stockholders’ equity to $9.8 million, from $67.7 million and $46.7 million respectively.
The NYSE delisted the shares after the company’s average global market capitalization over 30 trading days fell below $15 million. The company chose not to appeal, obtained OTCID quotation on March 4, 2026 under the symbol RBOT, and has applied to upgrade to the OTCQB market, with no assurance on future trading liquidity.
Vicarious Surgical Inc. is a pre-revenue medical device company developing the single-port Vicarious Surgical System, a robotic platform intended for minimally invasive ventral hernia and other abdominal procedures, which has not yet been authorized by the FDA.
The company ended December 31, 2025 with cash and cash equivalents of $2.6 million and short-term investments of $7.2 million, and an accumulated deficit of $246.1 million. Management believes these resources, after a March 6, 2026 headcount reduction, will fund operations only through the second quarter of 2026, creating substantial doubt about its ability to continue as a going concern.
On March 3, 2026, the New York Stock Exchange determined to suspend trading and commence delisting proceedings for Vicarious Surgical’s Class A common stock for failing to maintain a $15.0 million average global market capitalization requirement. The shares now trade on the OTCID market tier under the symbol RBOT, a significantly more limited market that may reduce liquidity and pressure the stock price.
Vicarious Surgical Inc. reported changes to executive compensation for two senior leaders. On March 4, 2026, the company entered into amendments to the Executive Employment Agreements for Adam Sachs, its President, and Sammy Khalifa, its Chief Technology Officer.
Under these amendments, Mr. Sachs agreed to voluntarily reduce his annual base salary to approximately $270,810, and Mr. Khalifa agreed to reduce his annual base salary to approximately $318,600. Despite these reductions, any target bonus amounts and severance payments under their employment agreements will continue to be calculated using the higher base salaries that were in effect immediately before these amendments. The amendments are filed as Exhibits 10.1 and 10.2.
Vicarious Surgical Inc. reports that the New York Stock Exchange has suspended trading in its common stock and begun proceedings to delist it. The NYSE determined the company no longer meets the continued listing requirement for an average global market capitalization of at least $15,000,000 over 30 trading days.
The company has received approval to have its shares quoted on the OTCID market operated by OTC Markets, and expects trading there to begin on March 4, 2026 under the symbol RBOT. Management notes that OTC quotation is a significantly more limited and less liquid market, which may reduce trading activity, pressure the share price, hinder equity fundraising, limit access to public capital markets, and weaken the company’s ability to offer equity incentives to employees.